HEALIOS K.K. (4593.T) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Sep 11Sep 16Sep 24Sep 29Oct 2Oct 7Oct 13Oct 16

Key dataOct 16, 2026

OpenJPY 283.00

From 52W high−47.12%

Volume1.16M

Market capJPY 28.08B

P/E (TTM)55.4x

P/S (TTM)475.9x

Div yield—

Key dataOct 16, 2026

Open

JPY 283.00

From 52W high

−47.12%

Volume

1.16M

Market cap

JPY 28.08B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−8.4x

P/E (TTM)

55.4x

RSI (14)

46.3

MomentumView details →

1D Return

−5.82%

YTD Return

+2.55%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

55.4x

EV/EBITDA

−8.4x

EV/Sales

366.1x

P/S (TTM)

475.9x

P/B (TTM)

3.2x

ProfitabilityView details →

Gross Margin

−109.62%

Net Margin

−2131.73%

EBITDA Margin

−2947.12%

ROE (TTM)

−45.25%

ROA (TTM)

−13.00%

Asset Turnover

0.01x

GrowthView details →

Revenue YoY

−81.43%

EPS YoY

+49.98%

FCF YoY

−81.93%

Revenue CAGR 3Y

+4.94%

EPS CAGR 3Y

+56.98%

EBITDA YoY

—

MomentumView details →

1D Return

−5.82%

YTD Return

+2.55%

1Y Return

−39.44%

RSI (14)

46.3

vs 50D SMA

−0.20%

vs 200D SMA

−11.49%

Capital & dividendView details →

Debt/Equity

0.42x

Current Ratio

2.00x

Quick Ratio

2.00x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

74.00M

Net Income (TTM)

−3.13B

Op. CF (TTM)

−3.67B

Next earningsNov 12, 2026 →

Latest newsMore news →

Helios completed shipment of the first order of its culture supernatant product worth 144 million yen to JENECELL.11d ago

Helios obtained a 'regenerative medicine product manufacturing and sales license' from the Hyogo Prefectural Governor.46d ago

Similar companies

SEIKAGAKU CORPORATION4548.T Innovacell Inc.504A.T MIZUHO MEDY CO.,LTD.4595.T Daito Pharmaceutical Co.,Ltd.4577.T Fuso Pharmaceutical Industries,Ltd.4538.T Fuji Pharma Co.,Ltd.4554.T Find similar companies →

Latest newsMore news →

Helios completed shipment of the first order of its culture supernatant product worth 144 million yen to JENECELL.11d ago Helios obtained a 'regenerative medicine product manufacturing and sales license' from the Hyogo Prefectural Governor.46d ago Healios announced that its low-immunogenicity iPS cell product 'Healios UDC' obtained a patent in China.59d ago